前列舒通胶囊对前列腺增生大鼠的治疗效果观察

Treatment of benign prostatic hyperplasia with Qianlieshutong capsule

目的探讨前列舒通胶囊治疗前列腺增生症大鼠的效果，并探讨其作用机制。方法健康雄性SPF级SD大鼠共60只，采用大鼠去势后注射丙酸睾酮致前列腺增生法造模。完全随机分为3组，各20只，即正常对照组（未造模、造模、蒸馏水5mg／kg）、未治疗组（造模、淀粉胶囊0．25g／kg以蒸馏水1ml配制成悬液灌胃）、前列舒通组（造模、前列舒通胶囊0．25g／kg以蒸馏水1ml配制成悬液灌胃），给药6周后处死，摘取大鼠前列腺并用电光分析天平称重获取前列腺指数，同时取前列腺组织行免疫组化染色，测定表皮生长因子（EGF）。结果前列舒通组大鼠膀胱压力[（6．0±1．3）cmH2O（1emH2O=0．098kPa）]、膀胱最大容积[（2．13±0．25）m1]、残余尿量[（44±5）μl]、前列腺指数[（2．00±0．30）mg／g]与未治疗组[分别为（5．4±1．7）cmH2O，（1．51±0．55）ml、（52±5）μl、（2．75-t-0.16）mg／g]相比差异均有统计学意义（均P〈0．05）。免疫组化染色结果显示，前列舒通组EGF表达率为（42．6±7．8）％，明显低于未治疗组[（75．2±8．8）％]，且差异有统计学意义（P〈0．05）。结论前列舒通可降低大鼠前列腺体积，其作用机制可能与前列舒通抑制前列腺组织中释放表皮生长因子有关。

Objective To observe the clinical effect of benign prostatic hyperplasia with Qianlieshutong treatment. Methods Rat model of benign prostatic hyperplasia was established by castration followed by injection of testosterone. The rats were randomly divided into 3 groups ： the normal group （ without building mode1, distilled water 5 mg/kg） , the notreatment group（building model, starch capsules 0.25 g/kg） , and Qianlieshutong group （building model, Qianlieshutong capsule 0.25 mg/kg）. The rats were sacrificed. The prostates were sampled and weighed and the prostate index was calculated. Immunohistochemical specimens were prepared and epidermal grouth factor （EGF） were investigated. Results Bladder pressure [ （6.0 ±1.3 ） cm H2O （ 1 cm H20 = 0. 098 kPa ], maximum bladder capacity [ （2. 13 ± 0.25）ml], residual urine volume [（44 ± 5）μl], and prostatic index [ （2.00 ± 0. 30）mg/g ] in Qinalieshutong group were significantly lower than those in notreatment group. From immunohistochemical specimens of EGF, EGF levels in Qinalieshutong group was （ 42. 6 ±7. 8 ） %, which significantly lower than those in notreatment group. Conclusions Qianlieshutong can decrease prostate weight of rats. Its mechanism may be related to the inhibition of prostate tissue releasing EGF.